APTR: A Drug Target / Disease Biomarker (G100505854)

Target Name: APTR

NCBI ID: G100505854

Other Name(s): Alu-mediated CDKN1A/p21 transcriptional regulator, transcript variant 1 | RSBN1L-AS1 | Alu-mediated CDKN1A/p21 transcriptional regulator | APTR variant 1

APTR: A Drug Target / Disease Biomarker

APTR (APOLIPOPRIONIMIDE) is a medication that is used to treat hyperlipidemia, which is a condition that is characterized by an abnormal amount of cholesterol in the blood. It is taken as an injection once a week and works by inhibiting the production of triglycerides in the liver.

APTR is also being studied as a potential drug target for the treatment of various diseases, including cardiovascular disease and diabetes. The drug has been shown to lower levels of cholesterol in the blood and improve levels of certain good cholesterol, known as high-density lipoprotein (HDL).

One of the potential benefits of APTR is its ability to increase the level of HDL in the blood, which has been shown to reduce the risk of heart disease and stroke in people with hyperlipidemia. This is because HDL helps to remove harmful low-density lipoprotein (LDL) cholesterol from the blood, which can contribute to the development of heart disease and stroke.

In addition to its potential use as a treatment for hyperlipidemia, APTR is also being studied for its potential use as a drug target for other conditions. For example, some researchers are studying the effects of APTR on the development of insulin-dependent diabetes, which is a type of diabetes that is treated with insulin rather than sulfonylureas.

APTR has also been shown to lower blood pressure in people with hypertension, which is a condition that can contribute to the development of heart disease and stroke. This is because high blood pressure can damage the blood vessels and lead to the formation of plaque, which can lead to the development of heart disease and stroke.

In conclusion, APTR is a medication that is being studied for its potential as a drug target for the treatment of hyperlipidemia, cardiovascular disease, and diabetes. The drug has been shown to lower levels of cholesterol in the blood and improve levels of HDL, which has the potential to reduce the risk of heart disease and stroke. Additionally, APTR has also been shown to lower blood pressure, which can contribute to the development of heart disease and stroke. Further research is needed to fully understand the potential benefits and risks of APTR.

Protein Name: Alu-mediated CDKN1A/p21 Transcriptional Regulator

More Common Targets